Pacific Edge Limited (PEB)

Overview

Pacific Edge Limited is a pioneering cancer diagnostic company, with its operations primarily focused on the research, development, and commercialization of innovative diagnostic and prognostic solutions aimed at enhancing the early detection and efficient management of cancers. Having established its presence in notable markets such as New Zealand, the United States, Australia, and Singapore, the company operates through two main segments: Commercial and Research. Since its inception in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited has been at the forefront of creating genomic urine tests for the detection and management of bladder cancer under its flagship brand, Cxbladder, alongside multiple other projects in development aimed at combatting various types of cancers.

Products and Services

Pacific Edge Limited offers an innovative range of products focused on the detection and management of cancer:

• Cxbladder: This is a suite of non-invasive genomic urine tests specifically designed for the detection and management of bladder cancer.
• Cxbladder Resolve is aimed at identifying patients who may have aggressive or more advanced stages of bladder cancer. This tool is crucial for determining the urgency and type of treatment that may be required.
• Cxbladder Triage is designed to help identify patients presenting with haematuria (the presence of blood in urine), who are at a low risk of having bladder cancer, potentially reducing unnecessary invasive tests for these individuals.
• Cxbladder Detect offers a non-invasive method for the detection of bladder and other urinary tract cancers, providing a valuable tool for initial diagnosis.
• Cxbladder Monitor allows for the regular monitoring of patients with a history of bladder cancer, aiding urologists in early detection of recurrences of the disease.
• In addition to these specialized bladder cancer diagnostic tools, Pacific Edge is expanding its research and development efforts to create diagnostic solutions for other types of cancer, including gastric, colorectal, endometrial cancers, and melanoma. These initiatives underline the company's commitment to broadening its impact on cancer diagnosis and management across a more diverse range of cancer types.